Friday, 6 November 2026European Markets

VRANKEN-POMMERY, L''OREAL, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - vranken-pommery (vrap.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
vranken-pommery (vrap.pa) €15.30 5.1% 2.66%
l''oreal (or.pa) €414.40 1.54% 21.72%
lotus bakeries (lotb.br) €7240.00 0.62% 19.81%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. vranken-pommery (vrap.pa)

5.1% forward dividend yield and 2.66% return on equity

vranken-pommery monopole société anonyme produces and sells wines and champagnes in europe, north america, and the asia pacific. it offers its products under the champagne charles lafitte, champagne demoiselle, champagne pommery, champagne heidsieck & c° monopole, champagne vranken – diamant, champagne germain, sao pedro, rozès, and grifo brands. vranken-pommery monopole société anonyme was founded in 1976 and is headquartered in reims, france.

earnings per share

as for profitability, vranken-pommery has a trailing twelve months eps of €1.15.

pe ratio

vranken-pommery has a trailing twelve months price to earnings ratio of 13.3. meaning, the purchaser of the share is investing €13.3 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.66%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vranken-pommery's stock is considered to be overbought (>=80).

volume

today's last reported volume for vranken-pommery is 425 which is 82.45% below its average volume of 2423.

dividend yield

according to morningstar, inc., the next dividend payment is on jul 11, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 5.1%.

more news about vranken-pommery.

2. l''oreal (or.pa)

1.54% forward dividend yield and 21.72% return on equity

l'oréal s.a., through its subsidiaries, manufactures and sells cosmetic products for women and men worldwide. the company operates through four divisions: consumer products, l'oréal luxe, professional products, and active cosmetics. it offers shampoos, hair care products, shower gels, skincare products, cleansers, hair colorants, deodorants, sun care products, make-up, perfumes, etc. the company provides its products under the l'oréal paris, garnier, maybelline new york, nyx professional makeup, stylenanda, essie, dark & lovely, mixa, magic mask, niley, lancôme, yves saint laurent, armani, kiehl's since 1851, halena rubinstein, biotherm, shu uemura, it cosmetics, ralph lauren fragrance, urban decay, mugler, valentino, viktor&rolf, azzaro, prada, cacharel, maison margela fragrance, diesel, yue sai, atelier colonge, carita, takami, l'oréal professionnel paris, kérastase, redken, matrix, pureology, pulp riot, la roche-posay, vichy, cerave, skinceuticals, decléor, and skinbetter science brands. it sells its products through distribution channels, such as hair salons, local stores, e-commerce, travel retail, mass market retail, department store perfumeries, pharmacies, drug stores, medi-spas, and branded retail. l'oréal s.a. was founded in 1909 and is headquartered in clichy, france.

earnings per share

as for profitability, l''oreal has a trailing twelve months eps of €10.84.

pe ratio

l''oreal has a trailing twelve months price to earnings ratio of 38.23. meaning, the purchaser of the share is investing €38.23 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.72%.

more news about l''oreal.

3. lotus bakeries (lotb.br)

0.62% forward dividend yield and 19.81% return on equity

lotus bakeries nv, together with its subsidiaries, engages in the provision of various snack products in belgium and internationally. the company offers biscuits, cookies, crackers, gingerbreads, cakes, cake specialties, waffles, and pepparkakor biscuits. it also provides energy bars, protein flapjacks, protein nut bars, healthy snacks, ice creams, and spreads. the company sells its products under the lotus, lotus biscoff, nakd, trek, bear, kiddylicious, peter's yard, dinosaurus, peijnenburg, snelle jelle, annas, lotus suzy, lotus tartélice lemon, kung oscar, and urban fruit brands. the company was founded in 1932 and is headquartered in lembeke, belgium. lotus bakeries nv is a subsidiary of stichting administratiekantoor van aandelen lotus bakeries.

earnings per share

as for profitability, lotus bakeries has a trailing twelve months eps of €136.84.

pe ratio

lotus bakeries has a trailing twelve months price to earnings ratio of 52.91. meaning, the purchaser of the share is investing €52.91 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.81%.

volume

today's last reported volume for lotus bakeries is 102 which is 91.48% below its average volume of 1198.

yearly top and bottom value

lotus bakeries's stock is valued at €7,240.00 at 21:30 est, under its 52-week high of €7,800.00 and way higher than its 52-week low of €5,630.00.

more news about lotus bakeries.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com